Several genes in the common 36 gene set may contribute to M-110 mediated inhibition of cell proliferation, but we focused on the expression of MIG6, because it encodes an important inhibitor of EGFR signaling [37, 38], suggesting that M-110 treatment of prostate cancer cells negatively affects signaling through the EGFR. Here, EGFR is linked to prostate carcinoma.